Making the Connection:
A Call to Action Against Undiagnosed Atrial Fibrillation

Sean Pokorney, MD, MBA
Duke Clinical Research Institute
Duke University
Raleigh, North Carolina

Emily P. Zeitler, MD, MHS, FACC, FHRS
Dartmouth Health
Geisel School of Medicine
The Dartmouth Institute
Lebanon, New Hampshire

Watch Now

Critical Conversations on Atrial Fibrillation: A MasterClass Series

1.0 CME/MOC/NCPD/CPE

Sean Pokorney, MD, MBA
Duke Clinical Research Institute
Duke University
Raleigh, North Carolina

Emily P. Zeitler, MD, MHS, FACC, FHRS
Dartmouth Health
Geisel School of Medicine
The Dartmouth Institute
Lebanon, New Hampshire

Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF.

Joe R. Anderson, PharmD, PhC
University of New Mexico College of Pharmacy
Albuquerque, New Mexico

Barry E. Bleske, PharmD, FCCP
University of New Mexico
University of Michigan, College of Pharmacy
Albuquerque, New Mexico

Watch Now

Taking the Pulse of Undiagnosed Atrial Fibrillation: Pharmacists as a Lynchpin of Detection and Team-Based Care

1.0 CME/CPE

Joe R. Anderson, PharmD, PhC
University of New Mexico College of Pharmacy
Albuquerque, New Mexico

Barry E. Bleske, PharmD, FCCP
University of New Mexico
University of Michigan, College of Pharmacy
Albuquerque, New Mexico

Screening and diagnosing atrial fibrillation (AF) is vital to implementing guideline-recommended treatment to reduce the risk of stroke. In this activity, an expert panel of pharmacists and a cardiologist discuss risk factors for AF, evidence-based strategies for screening and managing asymptomatic and symptomatic AF, and how multidisciplinary and interdisciplinary approaches to care increase screening and improve patient outcomes.

Coming Soon

Anticoagulation Therapy in NVAF: A Quality Improvement Initiative

0.5 CME/MOC/CNE/CPE

Clinician and patient barriers to anticoagulation therapy are quite common in the treatment setting of nonvalvular atrial fibrillation (NVAF). This activity will discuss real‐world challenges and offer practical strategies for addressing this public health and clinical practice gap. Learnings gained from a Quality Improvement initiative undertaken at University of Florida (UF) Health, including specific process improvements, will serve as a model for other health systems who may wish to replicate the UF Health initiative. The primary goal of this activity is to raise awareness of the problem of diagnosed but untreated NVAF, inspiring clinicians and health systems to undertake improvement efforts to close this treatment gap, while providing them with tools and resources which may aid in their endeavors.

Curriculum Description

Atrial fibrillation (AF) affects an estimated 2.7 to 6.1 million people in the United States—a number that is expected to increase as the population ages. The majority of patients with AF have nonvalvular atrial fibrillation (NVAF), which is associated with increased morbidity and mortality and is a significant risk factor for stroke. Anticoagulation reduces the risk for stroke by about 70%, and the latest guidelines recommend that patients with AF and risk factors for stroke receive anticoagulation therapy indefinitely.

In this collection of PeerView activities, we offer a concise but high-level overview of essential research and clinical data focused on the detection and management of NVAF, including guideline recommendations for the use of approved direct oral anticoagulants (DOACs) and best practices for screening and diagnosis.

Target Audience

These activities have been designed to meet the educational needs of family medicine/general practice physicians, cardiologists, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other physicians that may recognize or manage atrial fibrillation.

Playlist

Episode 1. Looking for Trouble: The Role of Systematic Screening

Sean Pokorney, MD, MBA

Episode 2. Profiles in Comorbidity: Identifying Who Is at High Risk

Sean Pokorney, MD, MBA

Episode 3. Mending the Healthcare System: Reducing Disparities

Sean Pokorney, MD, MBA

Episode 4. The Fear Factor: Mitigating Patients’ Concerns About Anticoagulation

Sean Pokorney, MD, MBA

Episode 5. State-of-the-Art Treatment: Catching Up With Current Guidelines

Sean Pokorney, MD, MBA

Episode 6. Is That Realistic? What We’ve Learned About Anticoagulation Therapy From Real-World Studies

Sean Pokorney, MD, MBA

Episode 7. Marching to Their Own Rhythm: Using Consumer Wearables in AF Diagnosis and Treatment

Sean Pokorney, MD, MBA

Taking the Pulse of Undiagnosed Atrial Fibrillation: Pharmacists as a Lynchpin of Detection and Team-Based Care

Joe R. Anderson, PharmD, PhC

Subscribe to Podcasts

Making the Connection:
A Call to Action Against Undiagnosed Atrial Fibrillation

Critical Conversations on Atrial Fibrillation: A MasterClass Series

Taking the Pulse of Undiagnosed Atrial Fibrillation: Pharmacists as a Lynchpin of Detection and Team-Based Care